Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHAROS: (R)-9bMS in Metastatic Castration-Resistant Prostate Cancer
NCT06705686Phase 1Recruiting
- Sponsor
- TechnoGenesys
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mahatinib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by TechnoGenesys. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Mar 2026; status: recruiting.
02
Drugs
mahatinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06705686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705686.